SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial

The Lancet Oncology 2026

View at publisher
Authors: Runbo Zhong, Huangming Hong, Min Yan, Qiming Wang, Yan Zhang, Qiongyu Lan, Yongzhong Luo, Ling Zhang, Haipeng Xu, Sanxing Guo, Wei Guo, Jie Ma
+19 more Longzhen Zhang, Lin Wu, Zhigang Liu, Wei He, Yubei Sun, Kai Chen, Jiangqiong Huang, Guang Han, Weiqi Nian, Ming Zhang, Shengxiang Ren, Rong Qiao, Xiang Li, Meijing Yu, Jin Hu, Yanhua Huang, Li Song, Wei Shi, Hua Zhong
DOI: 10.1016/s1470-2045(26)00238-x
Cited by: 1
References: 26

Fields of Study & Subjects

HER2/EGFR in Cancer Research Wnt/β-catenin signaling in development and cancer Mast cells and histamine

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
9
Pages
1146–1157
Publication date
24 August 2026
Language
EN